What Eufilina Treats: Main Uses and Benefits

The use of Eufilina (Aminophylline) is associated with the supportive management of conditions involving reversible airflow obstruction. This medication is considered relevant for managing symptoms such as wheezing and shortness of breath associated with asthma, chronic bronchitis, and emphysema.

It is applied across domains where additional symptomatic support is needed to ease symptoms related to heightened physiological activity, especially acute wheezing and severe difficulty breathing. This support is relevant in clinical settings that involve acute or unstable symptom patterns, such as sudden, severe exacerbations of chronic lung conditions. It provides support that helps ease the overall symptom burden during difficult episodes.

Eufilina is relevant for addressing symptom clusters that may become intense or disruptive, focusing on manifestations that arise directly from bronchial muscle constriction and lead to chest tightness. It may assist with managing symptoms that create noticeable functional strain, supporting the patient during difficult episodes by easing distress and contributing to general well-being during symptomatic phases.

---

Quick Fact: Relief for Airflow Obstruction Symptoms

Eufilina is commonly used across conditions presenting with episodic or fluctuating manifestations of difficulty breathing. Its role is to provide support that helps ease the overall symptom burden and contributes to improved day-to-day comfort during symptomatic periods.

Regulatory References

1. NIH MedlinePlus overview

The use of Eufilina is defined by official regulatory criteria that classify who can safely use the medicine and who must avoid it. The drug is typically approved for use in adults and adolescents to manage reversible airway obstruction.

Contraindicated Populations

Use is strictly contraindicated in patients with a documented hypersensitivity to theophylline or any formulation component, and in individuals with Acute Porphyria. Use is also prohibited if the patient is concurrently taking other xanthine-containing medicines, such as specific enzyme-inhibiting drugs like Riociguat.

Restricted and Conditional Use

Official regulatory labeling defines several populations requiring restricted use or close monitoring. This includes older adults (ge 60 years) and infants (le 1 year) due to slower, more unpredictable drug clearance. Patients with severe conditions like hepatic impairment (liver disease) or Congestive Heart Failure must use Eufilina only under caution, as these conditions significantly reduce drug elimination. The medicine should also be used cautiously in patients with a history of seizures or active stomach ulcers, which the drug may exacerbate.

For pregnancy and lactation, Eufilina use is restricted and only permitted when the clinical benefit outweighs the potential risk to the fetus or nursing infant.

Interactions with other medicines and products

Eufilina, whose active component is Theophylline, has officially documented interaction profiles based on changes to its clearance and pharmacodynamic effects.

Contraindicated Combinations and Restrictions

Co-administration with other xanthine derivatives, including Theophylline itself, is a formally documented contraindicated combination due to the high risk of severe toxicity as outlined in regulatory labeling.

Exposure-Modifying Substances

Many medicinal products alter Theophylline's plasma concentrations by inhibiting or inducing the hepatic Cytochrome P-450 (CYP) enzymes involved in its metabolism.

• Substances that Increase Theophylline Levels (Reduce Clearance): Officially listed agents include Cimetidine, Macrolide Antibiotics (e.g., Erythromycin), Quinolone Antibiotics (e.g., Ciprofloxacin), Oral Contraceptives, and Influenza Vaccine.
• Substances that Decrease Theophylline Levels (Increase Clearance): Regulatory documents list agents such as Rifampicin and Antiepileptics (e.g., Phenytoin).

Other Documented Interactions

Pharmacodynamic synergy exists with Sympathomimetics (e.g., beta2-agonists), increasing the documented risk of cardiac arrhythmias and hypokalaemia. Theophylline also antagonizes the cardiovascular effects of Adenosine. Non-drug interactions include a reduction in clearance documented in the Elderly and in patients with Liver disease, and altered clearance based on smoking status or consumption of St John's Wort.

How Eufilina Works

Eufilina's action is exerted through a dual-mechanistic approach involving cellular enzyme systems and receptor antagonism, and involves effects on pulmonary and cardiovascular physiological processes.

---

Modulating Airway Muscle Tone by Inhibiting PDE

This domain describes how the drug blocks Phosphodiesterase (PDE) enzymes, which are responsible for breaking down the internal cellular messenger, cAMP. Preventing this breakdown causes cAMP levels to rise, which triggers a sequence of events leading to the relaxation of bronchial smooth muscle and the resulting bronchodilation (increased diameter of the bronchial lumen).

---

Countering Constricting Signals via Adenosine Receptors

This mechanism focuses on Eufilina's role as a competitive antagonist of adenosine receptors. By binding to these receptors, Eufilina blocks the action of the natural molecule adenosine, which would otherwise signal the airways to constrict. This mechanistic action operates in parallel with the smooth muscle relaxation and contributes to the modulation of airway hyper-reactivity.

---

Influencing Cellular Inflammatory Pathways

Beyond its direct effects on muscle tone, Eufilina’s mechanism of increasing cAMP also extends to modulating inflammatory processes at a cellular level. The mechanism involves the influence of cellular signals by suppressing the release of certain chemical mediators. This action assists in the modification of inflammatory signaling cascades.

Eufilina (Aminophylline) administration follows a specific protocol that utilizes distinct routes and regimens depending on the therapeutic goal. The official usage protocol reserves intravenous (IV) infusion for acute, immediate needs requiring rapid systemic effect, typically administered in a controlled clinical setting. Oral forms (tablets or solution) are designated for ongoing, long-term maintenance therapy.

Dosing is a highly procedural process that must be calculated and monitored individually. All IV doses, including the initial loading dose of 5.7 mg/kg, must be calculated based on the patient’s Ideal Body Weight (IBW), not actual weight. This dosing is rigorously guided by the measurement of serum theophylline concentrations to ensure levels remain within the narrow therapeutic range.

Specific procedural constraints govern the IV route: the loading dose requires dilution and must be infused slowly, typically over 30 minutes, with the rate strictly not exceeding 25 mg/minute. Furthermore, administration must account for patient factors. Older adults, as well as individuals with hepatic or cardiac impairment, require substantially reduced maintenance dose rates, while smokers may require higher rates due to altered drug clearance. Oral extended-release tablets must be swallowed whole to maintain their intended release profile.

Research evidence / Overview of studies for Eufilina

Evidence for use in Acute Exacerbations of Asthma

Researchers conducted numerous controlled trials and large-scale reviews to examine Eufilina's role in acute asthma when added to standard medical care. These studies focused on patients experiencing severe, acute episodes of difficulty breathing where symptoms were fluctuating or unstable. Researchers recorded and tracked physiological measures (such as spirometric values used to assess airflow through the lungs), changes in asthma severity scores, and healthcare utilization metrics including hospitalization and Intensive Care Unit (ICU) admission.

Findings regarding overall patient outcomes when Eufilina was added to standard care were mixed across large evidence reviews. Pooled data from meta-analyses indicated that observations of patient hospitalization rates, ICU admission rates, or overall severity scores between the groups receiving the medication and the control groups did not consistently differ. Similarly, studies monitoring airflow measurements generally found that the patterns of change in these measurements were not consistently different compared to standard therapy alone. Evidence consistency remains low due to clinical heterogeneity across the included studies, such as variations in patient populations and the use of different drug dosages. This means the findings were mixed.

Evidence for use in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)

Studies exploring Eufilina for acute COPD exacerbations examined whether the medication was associated with changes in temporary physiological imbalance. The research base is composed mainly of smaller non-randomized cohort studies focusing on specific, severe patient groups. Outcomes related to systemic or functional imbalance were monitored, specifically measuring changes in arterial blood gas parameters, such as carbon dioxide levels ( PaCO2) and oxygenation indices, as well as patient-reported outcomes describing perceived discomfort (dyspnea severity scores).

Studies focusing on a very specific subgroup of patients—those with severe, refractory exacerbations who still had elevated CO2 levels after receiving maximal standard treatment—reported patterns of change in PaCO2 levels and dyspnea severity scores. However, other short-term randomized trials, including general AECOPD populations, reported no difference in post-bronchodilator lung function over the observed periods. Evidence remains limited and is mainly derived from the small, specialized studies, which provides limited insight for the broader population of patients experiencing COPD exacerbations.

Duration of Observation in Studies and Long-term Follow-up

All research for Eufilina was conducted during periods of acute episodes in acute care settings. Therefore, the evidence focuses on short-term symptom changes, with outcomes typically measured within 2, 6, 12, or 24 hours after treatment begins. Follow-up durations were limited, often being tied to the patient's Length of Hospital Stay (LOHS). Long-term effects are not fully established, and there is limited information for long-term outcomes related to this medication's use beyond the immediate acute phase of treatment.

Key Studies & References A narrative review of theophylline: is there still a place for an old friend?

Common questions about Eufilina (FAQ)

Q: What happens if I forget to take Eufilina?

A: Regulatory documents state that if a dose is missed, decisions regarding subsequent doses are often based on whether a patient exhibits signs of toxicity, which can occur if drug levels are too high. Official information emphasizes that a healthcare provider can establish an individualized action plan for a missed dose scenario.

Q: Is Eufilina safe for people who have kidney issues?

A: Official information indicates that use is cautioned in infants under 3 months of age who have reduced renal function (kidney function), as this can slow how the drug is cleared from the body. For older children and adults, while kidney issues may be a factor considered for dose management, official labeling does not describe a general contraindication for use in the presence of kidney disease.

Q: Is it normal to feel a little dizzy when starting Eufilina?

A: Official documents list dizziness and lightheadedness as possible side effects associated with the medication. The official documents emphasize the importance of communicating side effects to a healthcare professional.

Q: Are there generic versions of Eufilina available?

A: The active ingredient in Eufilina, Aminophylline, is commonly available in generic form. Drug databases confirm the existence of generic versions.

Q: Does Eufilina have any warnings about driving or operating machinery?

A: The regulatory label indicates that caution is necessary when performing activities such as driving, operating machinery, or engaging in other hazardous activities. This warning is in place because the drug may potentially cause side effects like dizziness or drowsiness.

Q: Does Eufilina cause weight gain or weight loss?

A: Regulatory documents list weight loss and a decreased appetite as potential side effects of this medication.

Q: How quickly does Eufilina leave the body?

A: Official pharmacological information indicates that the rate at which the active drug, theophylline, is removed from the body (clearance) can vary widely among individuals. This clearance rate is influenced by several factors, including a person's age, whether they have certain illnesses, and if they are taking other medications at the same time.

Q: Is Eufilina a controlled substance?

A: According to regulatory classification bodies, Aminophylline (the active component of Eufilina) is not classified as a controlled substance under the U.S. Controlled Substances Act.

Q: Can I combine Eufilina with vitamin supplements?

A: Due to the drug's documented interaction profile with many medications and herbal supplements, official labeling indicates that the use of vitamins and any other supplements is a matter to be discussed with a healthcare professional. This allows them to assess the overall risk of potential interactions.

Q: Is Eufilina a recently developed medicine?

A: Official regulatory and research documents frequently discuss the drug's clinical use and mechanism using long-established historical context. The official record indicates that the drug has been widely studied for many decades.

The storage and disposal of Eufilina (Aminophylline) must strictly follow the conditions defined in regulatory labeling to maintain stability and ensure safety.

Storage Requirements

Condition	Requirement
Temperature	Store below 30 C and at room temperature; do not freeze.
Protection	Must be protected from light, excessive heat, and moisture.
Container	Oral forms must be kept in a closed container.

The medicine must be stored out of the sight and reach of children. Single-dose injection vials must be discarded after use, and the solution should be inspected for any crystals or discoloration before administration.

Disposal Instructions

Unused or expired Eufilina must be disposed of in accordance with local requirements. Patients are advised to utilize a medicine take-back program if available. The oral form should not be flushed down the toilet.